<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04515927</url>
  </required_header>
  <id_info>
    <org_study_id>JS002-004</org_study_id>
    <nct_id>NCT04515927</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of JS002 in HoFH Patients</brief_title>
  <official_title>An Open-label, Single-arm Study Evaluated the Efficacy and Safety of JS002 in Patients With Homozygous Familial Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      JS002 is a recombinant human anti-PCSK9 monoclonal antibody. This phase II open-label,&#xD;
      single-arm study aims to evaluate the efficacy and safety of JS002 in patients with&#xD;
      homozygous familial hypercholesterolemia A dose group (450 mg) was set up in this&#xD;
      study.Thirty subjects are planned to be enrolled.&#xD;
&#xD;
      Each subject required a maximum of 6 weeks of screening, 52 weeks of treatment, and 8 weeks&#xD;
      of follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2020</start_date>
  <completion_date type="Anticipated">July 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 6, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of effectiveness</measure>
    <time_frame>JS002 is administered subcutaneously every 4 weeks, from 12 or 52 weeks after initial administration</time_frame>
    <description>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hyperlipemia</condition>
  <arm_group>
    <arm_group_label>subcutaneous injection of JS002, 450mg, Q4W, 3/13 times.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JS002</intervention_name>
    <description>Biological: JS002 Administered by subcutaneous injection</description>
    <arm_group_label>subcutaneous injection of JS002, 450mg, Q4W, 3/13 times.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent.&#xD;
&#xD;
          2. Age ≥12 and ≤75 years old;&#xD;
&#xD;
          3. Weight ≥40kg at the time of screening&#xD;
&#xD;
          4. Patients diagnosed with HoFH&#xD;
&#xD;
          5. Low-density lipoprotein cholesterol (LDL-C) level ≥3.4mmol/L at the time of screening&#xD;
&#xD;
          6. Fasting triglycerides ≤4.5 mmol/L;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of NYHA class III-IV heart failure or EF&lt;30%&#xD;
&#xD;
          2. History of uncontrolled arrhythmia within 3 months&#xD;
&#xD;
          3. History of MI,UA, PCI or CABG, stroke within 3 months.&#xD;
&#xD;
          4. History of DVT or pulmonary embolism within 3 months.&#xD;
&#xD;
          5. Planned cardiac surgery or revascularization.&#xD;
&#xD;
          6. Uncontrolled hypertension.&#xD;
&#xD;
          7. Uncontrolled diabetes mellitius (HbA1c&gt;8.0%）.&#xD;
&#xD;
          8. Other conditions that the researchers considered inappropriate to participate in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Runfa Zhang</last_name>
    <phone>8610-81028077</phone>
    <email>runfa_zhang@junshipharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Jie</last_name>
      <phone>8610-81028077</phone>
      <email>injie1998@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

